Ahmad Bilal Repare Therapeutics plans to prioritize its clinical-stage oncology drug candidates, which will result in the reduction of around 25% of its workforce. The company said it will focus on developing its drug candidates lunresertib, camonsertib, RP-1664 and RP-3467, while reducing the size of its preclinical research and discovery operations. Most of the layoffs are expected to occur in the preclinical division, according to a statement .
Repare expects to incur cash payments of around $1.5M to $2M in Q3 related to the workforce reductions, which are expected to generate approximately $15M in annual savings and extend its cash runway into the latter half of 2026. More on Repare Therapeutics Repare gets FDA fast track status for ovarian cancer drug combo Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare Therapeutics.
